Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL10417396 | 0.81 | — | — | |
| SCHEMBL8919707 | 0.79 | CA1 (0.40) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL998262 | 0.79 | ALDH1A1 (0.38) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL1032872 | 0.79 | CA1 (0.40) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL30952527 | 0.79 | CA1 (0.40) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL9142584 | 0.78 | ALDH1A1 (0.32) | ALDH1A1LMNA | |
| SCHEMBL29690296 | 0.77 | ALDH1A1 (0.36) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL1462129 | 0.77 | ALDH1A1 (0.36) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL30688718 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CA1CA2PTK2 | |
| SCHEMBL5513285 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CA1CA2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011311-A | Preparation method of metal nanocluster confined covalent organic framework composite material | 西北工业大学 | 2026-05-12 | — | — | CN | claimed |
| CN-118185500-A | High-frequency low-loss insulating adhesive film and preparation method thereof | 福建臻璟新材料科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2003103832-A2 | OXYGEN REDUCTION CATALYST | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2003-12-18 | — | — | WO | claimed |
| US-20030228972-A1 | Using cobalt containing coordination catalyst | UNIVERSITY TECHNOLOGIES INTERNATIONAL, INC. (CA) | 2003-12-11 | — | — | US | claimed |
| CN-122036621-A | Fluorine substituted benzimidazolyl aniline compound and synthetic method and application thereof | 中茂绿能科技(西安)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122011311-A | Preparation method of metal nanocluster confined covalent organic framework composite material | 西北工业大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250331419-A1 | COMPOUND, LIGHT EMITTING MATERIAL, AND ORGANIC LIGHT EMITTING DEVICE | KYULUX INC (JP) | 2025-10-23 | — | — | US | disclosed |
| CN-119095850-A | Compound, light-emitting material, and organic light-emitting element | 九州有机光材股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118185500-A | High-frequency low-loss insulating adhesive film and preparation method thereof | 福建臻璟新材料科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240132479-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2024-04-25 | — | — | US | disclosed |
| WO-2023210192-A1 | COMPOUND, LIGHT-EMITTING MATERIAL, AND ORGANIC LIGHT-EMITTING DEVICE | 株式会社Kyulux | 2023-11-02 | — | — | WO | disclosed |
| WO-2022165198-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2022-08-04 | — | — | WO | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5449584-A | Positive photo-sensitive resin composition comprising a photosensitive polybenzoxazole or a mixture of a polybenzoxazole, an organic solvent soluble polymer and a diazoquinone and/or a dihydropyridine compound | SUMITOMO BAKELITE COMPANY, LTD. (JP) | 1995-09-12 | — | — | US | disclosed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| EP-0459395-A2 | Positive photo-sensitive resin composition | SUMITOMO BAKELITE COMPANY LIMITED (JP) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132479-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | CUTA, DCXR, PLOD3 | ALDH1A1 349/4885LMNA 555/4885CA12 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.